Hospital & Healthcare Services · Founded 1979 · www.apollohospitals.com · BSE 508869 · NSE APOLLO HOSP. · ISIN INE437A01024
No Notes Added Yet
Business
Apollo Hospitals Enterprise Ltd. is one of India's largest integrated healthcare providers. Its core business revolves around providing tertiary and quaternary care hospital services across various specialties. The company operates a chain of multi-specialty hospitals, runs a large network of retail pharmacies (Apollo Pharmacy), and also offers primary care clinics, diagnostic centers, and telemedicine services. It makes money primarily through patient fees for medical services, procedures, and surgeries, sales of pharmaceutical products, and charges for diagnostic tests and consultations.
Revenue Mix
While specific revenue contribution figures are not provided, Apollo Hospitals primarily operates through three main segments:
Hospital Services: This is the largest segment, comprising the income generated from medical, surgical, and other healthcare services provided at its multi-specialty hospitals. This includes inpatient and outpatient services, emergency care, organ transplants, and specialized treatments.
Pharmacy Retail: Operated under the "Apollo Pharmacy" brand, this segment involves the sale of medicines, over-the-counter products, and wellness items through a nationwide chain of retail outlets. This is a significant revenue generator and a high-growth area.
Other Healthcare Services: This segment includes revenue from primary care clinics (Apollo Clinics), diagnostic services, health insurance services, medical education, telemedicine, and health IT services.
Industry
The Indian healthcare industry is characterized by significant growth, driven by an aging population, rising disposable incomes, increasing awareness, and a growing burden of chronic diseases. It is a fragmented industry with a mix of public and private players. Apollo Hospitals is a leading player in the private healthcare sector, often considered a pioneer. It holds a dominant position due to its extensive network of hospitals, reputation for complex medical procedures, and comprehensive service offerings, positioning it as a preferred choice for high-quality, advanced medical care in India and for medical tourism.
MOAT
Apollo Hospitals possesses several durable competitive advantages:
Brand Reputation & Trust: Decades of operation have built a strong brand name synonymous with quality, advanced medical care, and patient trust across India, making it a preferred choice for complex treatments.
Scale & Network: As one of the largest private hospital chains with a widespread presence, it benefits from economies of scale in procurement, shared resources, and a broad patient referral network. Its extensive pharmacy chain further strengthens its presence.
Talent Pool: Its reputation and scale attract a large pool of highly skilled doctors, surgeons, and medical professionals, which is crucial in the healthcare industry.
Integrated Model: The comprehensive ecosystem of hospitals, pharmacies, clinics, and diagnostics creates patient stickiness and opportunities for cross-selling.
Growth Drivers
Key factors that can drive growth for Apollo Hospitals over the next 3-5 years include:
Increasing Healthcare Expenditure: Rising per capita income and health consciousness in India are leading to greater spending on private healthcare.
Rising Disease Burden: An increase in lifestyle diseases and chronic conditions necessitates more advanced medical interventions.
Health Insurance Penetration: Growing penetration of health insurance will improve affordability and increase access to private healthcare services.
Medical Tourism: India's cost-effective and high-quality medical treatments attract international patients, with Apollo being a major beneficiary.
Expansion & Digital Health: Continued expansion of its hospital, pharmacy, and clinic network, along with investments in telemedicine and digital health platforms, will broaden its reach.
Risks
Regulatory & Pricing Pressure: Government policies on healthcare pricing, drug price controls, and changes in regulatory frameworks can impact profitability.
Competition: Intense competition from other large hospital chains, regional players, and single-specialty hospitals in key markets.
Talent Acquisition & Retention: Shortage of skilled medical professionals (doctors, nurses) and rising compensation costs can impact operational efficiency and margins.
Capital-Intensive Business: Hospital expansion is highly capital-intensive, requiring significant investment and leading to high debt levels if not managed prudently.
Healthcare Inflation: Rising costs of medical equipment, consumables, and drugs can put pressure on margins.
Litigation Risk: Healthcare providers are exposed to risks of medical malpractice lawsuits.
Management & Ownership
Apollo Hospitals was founded by Dr. Prathap C. Reddy in 1983, and the Reddy family continues to be the promoters and plays a crucial role in its management. The company is professionally managed with a blend of family members and experienced professionals on its board and leadership team. The long-standing involvement of the founding family provides stability and deep industry knowledge, having pioneered private healthcare in India.
Outlook
Apollo Hospitals is well-positioned to capitalize on the robust growth trajectory of the Indian healthcare sector, driven by its established brand, extensive network, and integrated service offerings. Its focus on tertiary care, expanding pharmacy network, and digital health initiatives provide strong avenues for future growth. However, the company faces inherent risks associated with regulatory interventions, intense competition, the capital-intensive nature of hospital expansion, and the ongoing challenge of attracting and retaining top medical talent. Its ability to navigate these challenges while continuing to expand its footprint and maintain service quality will be key to its sustained success.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 4851 | 4944 | 5086 | 5589 | 5527 | 5592 | 5842 | 6304 | 6477 | 6606 |
| Other Income | 28 | 28 | 37 | 38 | 64 | 61 | 40 | 55 | 53 | 44 |
| Total Income | 4878 | 4972 | 5123 | 5628 | 5591 | 5653 | 5882 | 6358 | 6530 | 6649 |
| Total Expenditure | 4237 | 4303 | 4411 | 4774 | 4765 | 4823 | 4990 | 5362 | 5512 | 5595 |
| Operating Profit | 642 | 669 | 712 | 854 | 825 | 831 | 892 | 996 | 1018 | 1055 |
| Interest | 113 | 119 | 116 | 118 | 110 | 115 | 108 | 110 | 113 | 119 |
| Depreciation | 167 | 190 | 177 | 185 | 185 | 211 | 215 | 218 | 219 | 224 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -19 | 0 |
| Profit Before Tax | 362 | 360 | 419 | 552 | 531 | 505 | 569 | 668 | 667 | 711 |
| Provision for Tax | 109 | 110 | 115 | 162 | 157 | 101 | 142 | 181 | 166 | 170 |
| Profit After Tax | 253 | 250 | 304 | 390 | 374 | 404 | 427 | 488 | 501 | 541 |
| Adjustments | -8 | 4 | 1 | -11 | -2 | -14 | 5 | -11 | 1 | -12 |
| Profit After Adjustments | 245 | 254 | 305 | 379 | 372 | 390 | 433 | 477 | 502 | 529 |
| Adjusted Earnings Per Share | 17.1 | 17.6 | 21.2 | 26.3 | 25.9 | 27.1 | 30.1 | 33.2 | 34.9 | 36.8 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 5178 | 6215 | 7256 | 8243 | 9617 | 11247 | 10560 | 14663 | 16613 | 19059 | 21794 | 25229 |
| Other Income | 37 | 53 | 44 | 34 | 32 | 33 | 49 | 78 | 90 | 106 | 200 | 192 |
| Total Income | 5215 | 6267 | 7300 | 8277 | 9650 | 11280 | 10609 | 14741 | 16703 | 19166 | 21994 | 25419 |
| Total Expenditure | 4444 | 5534 | 6549 | 7452 | 8555 | 9666 | 9427 | 12478 | 14563 | 16669 | 18772 | 21459 |
| Operating Profit | 771 | 733 | 751 | 825 | 1095 | 1614 | 1182 | 2263 | 2140 | 2497 | 3222 | 3961 |
| Interest | 118 | 180 | 257 | 295 | 327 | 533 | 449 | 379 | 381 | 449 | 459 | 450 |
| Depreciation | 212 | 264 | 314 | 359 | 396 | 620 | 573 | 601 | 615 | 687 | 758 | 876 |
| Exceptional Income / Expenses | 13 | 16 | 0 | 0 | 0 | 198 | 61 | 294 | 0 | 2 | 0 | -19 |
| Profit Before Tax | 455 | 332 | 222 | 171 | 373 | 660 | 221 | 1578 | 1144 | 1381 | 2039 | 2615 |
| Provision for Tax | 130 | 97 | 91 | 112 | 173 | 225 | 85 | 477 | 256 | 446 | 534 | 659 |
| Profit After Tax | 325 | 235 | 131 | 60 | 199 | 435 | 136 | 1101 | 888 | 935 | 1505 | 1957 |
| Adjustments | 14 | -9 | 90 | 58 | 37 | 20 | 14 | -46 | -68 | -36 | -59 | -17 |
| Profit After Adjustments | 340 | 226 | 221 | 117 | 236 | 455 | 150 | 1056 | 819 | 899 | 1446 | 1941 |
| Adjusted Earnings Per Share | 24.4 | 16.2 | 15.9 | 8.4 | 17 | 32.7 | 10.5 | 73.4 | 57 | 62.5 | 100.5 | 135 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 14% | 14% | 14% | 15% |
| Operating Profit CAGR | 29% | 12% | 15% | 15% |
| PAT CAGR | 61% | 11% | 28% | 17% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 17% | 18% | 20% | 19% |
| ROE Average | 21% | 17% | 15% | 11% |
| ROCE Average | 21% | 19% | 19% | 14% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 3171 | 3331 | 3313 | 3252 | 3334 | 3339 | 4603 | 5623 | 6197 | 6935 | 8212 |
| Minority's Interest | 73 | 78 | 125 | 132 | 136 | 131 | 200 | 280 | 334 | 385 | 441 |
| Borrowings | 1728 | 2450 | 2953 | 2924 | 2952 | 2852 | 2473 | 2427 | 1938 | 2236 | 4417 |
| Other Non-Current Liabilities | 410 | 251 | 1445 | 1499 | 1661 | 3631 | 3117 | 3815 | 4288 | 2798 | 3361 |
| Total Current Liabilities | 1076 | 1250 | 963 | 1567 | 1955 | 2337 | 2038 | 2434 | 3325 | 4665 | 4579 |
| Total Liabilities | 6459 | 7360 | 8800 | 9374 | 10037 | 12290 | 12431 | 14579 | 16082 | 17019 | 21011 |
| Fixed Assets | 3244 | 3997 | 4583 | 4766 | 4975 | 7426 | 6773 | 8291 | 8516 | 9661 | 10985 |
| Other Non-Current Assets | 1276 | 1388 | 2087 | 2389 | 2781 | 2217 | 2016 | 2228 | 3229 | 2079 | 2996 |
| Total Current Assets | 1939 | 1975 | 2129 | 2220 | 2282 | 2647 | 3642 | 4061 | 4337 | 5280 | 7029 |
| Total Assets | 6459 | 7360 | 8800 | 9374 | 10037 | 12290 | 12431 | 14579 | 16082 | 17019 | 21011 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 274 | 340 | 335 | 283 | 306 | 286 | 381 | 389 | 546 | 434 | 506 |
| Cash Flow from Operating Activities | 470 | 597 | 623 | 537 | 905 | 1293 | 1265 | 1696 | 1377 | 1920 | 2136 |
| Cash Flow from Investing Activities | -759 | -888 | -1152 | -405 | -711 | -289 | -863 | -847 | -871 | -1537 | -3381 |
| Cash Flow from Financing Activities | 392 | 330 | 477 | -108 | -215 | -910 | -340 | -792 | -633 | -311 | 1317 |
| Net Cash Inflow / Outflow | 103 | 39 | -52 | 24 | -20 | 95 | 61 | 57 | -127 | 72 | 73 |
| Closing Cash & Cash Equivalent | 377 | 379 | 283 | 306 | 286 | 381 | 425 | 547 | 433 | 506 | 578 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 24.43 | 16.23 | 15.88 | 8.44 | 16.95 | 32.68 | 10.46 | 73.41 | 56.96 | 62.49 | 100.55 |
| CEPS(Rs) | 38.6 | 35.87 | 32 | 30.09 | 42.72 | 75.76 | 49.31 | 118.34 | 104.51 | 112.8 | 157.34 |
| DPS(Rs) | 5.75 | 6 | 6 | 5 | 6 | 6 | 3 | 11.75 | 15 | 16 | 19 |
| Book NAV/Share(Rs) | 227.87 | 238.81 | 237.25 | 233.02 | 238.71 | 239.1 | 319.08 | 389.89 | 424.53 | 469.76 | 550.72 |
| Core EBITDA Margin(%) | 14.19 | 10.95 | 9.74 | 9.6 | 11.05 | 14.06 | 10.73 | 14.9 | 12.34 | 12.54 | 13.87 |
| EBIT Margin(%) | 11.07 | 8.24 | 6.61 | 5.66 | 7.27 | 10.61 | 6.34 | 13.34 | 9.18 | 9.6 | 11.46 |
| Pre Tax Margin(%) | 8.79 | 5.34 | 3.06 | 2.08 | 3.87 | 5.87 | 2.09 | 10.76 | 6.88 | 7.24 | 9.36 |
| PAT Margin (%) | 6.28 | 3.79 | 1.81 | 0.72 | 2.07 | 3.87 | 1.29 | 7.51 | 5.34 | 4.91 | 6.91 |
| Cash Profit Margin (%) | 10.37 | 8.03 | 6.14 | 5.08 | 6.18 | 9.38 | 6.71 | 11.61 | 9.05 | 8.51 | 10.38 |
| ROA(%) | 5.51 | 3.4 | 1.62 | 0.66 | 2.05 | 3.9 | 1.1 | 8.15 | 5.79 | 5.65 | 7.92 |
| ROE(%) | 10.59 | 7.25 | 3.96 | 1.82 | 6.07 | 13.08 | 3.44 | 21.6 | 15.16 | 14.54 | 20.51 |
| ROCE(%) | 12.09 | 9.05 | 7.62 | 7.12 | 10.24 | 17.13 | 9.32 | 24.92 | 17.78 | 19.27 | 21.19 |
| Receivable days | 39.79 | 35.79 | 34.21 | 34.88 | 35.08 | 33.27 | 40.76 | 38.53 | 43.93 | 45.47 | 46.32 |
| Inventory Days | 22.16 | 22.21 | 21.96 | 22.86 | 21.83 | 21.46 | 17.06 | 8.48 | 9.03 | 8.14 | 7.88 |
| Payable days | 49.46 | 57.91 | 53.32 | 50.11 | 51.65 | 53.83 | 66.42 | 67.27 | 75.5 | 79.74 | 74.37 |
| PER(x) | 55.89 | 81.6 | 73.45 | 125.91 | 72.02 | 34.82 | 277.55 | 61.52 | 75.66 | 101.65 | 65.86 |
| Price/Book(x) | 5.99 | 5.55 | 4.92 | 4.56 | 5.11 | 4.76 | 9.1 | 11.58 | 10.15 | 13.52 | 12.02 |
| Dividend Yield(%) | 0.42 | 0.45 | 0.51 | 0.47 | 0.49 | 0.53 | 0.1 | 0.26 | 0.35 | 0.25 | 0.29 |
| EV/Net Sales(x) | 3.98 | 3.36 | 2.6 | 2.16 | 2.11 | 1.69 | 4.16 | 4.55 | 3.85 | 4.91 | 4.55 |
| EV/Core EBITDA(x) | 26.72 | 28.49 | 25.08 | 21.56 | 18.56 | 11.75 | 37.12 | 29.45 | 29.86 | 37.47 | 30.77 |
| Net Sales Growth(%) | 18.12 | 20.01 | 16.75 | 13.61 | 16.67 | 16.94 | -6.11 | 38.85 | 13.3 | 14.73 | 14.35 |
| EBIT Growth(%) | 8.97 | -10.66 | -6.39 | -2.69 | 49.96 | 70.5 | -43.84 | 192.09 | -22.09 | 20.03 | 36.49 |
| PAT Growth(%) | 6.71 | -27.71 | -44.26 | -54.58 | 234.47 | 118.32 | -68.73 | 709.63 | -19.4 | 5.35 | 60.97 |
| EPS Growth(%) | 7.31 | -33.56 | -2.14 | -46.87 | 100.88 | 92.75 | -68 | 601.86 | -22.4 | 9.71 | 60.91 |
| Debt/Equity(x) | 0.63 | 0.85 | 0.95 | 1.06 | 1.1 | 1.08 | 0.62 | 0.47 | 0.44 | 0.47 | 0.67 |
| Current Ratio(x) | 1.8 | 1.58 | 2.21 | 1.42 | 1.17 | 1.13 | 1.79 | 1.67 | 1.3 | 1.13 | 1.54 |
| Quick Ratio(x) | 1.48 | 1.25 | 1.73 | 1.06 | 0.87 | 0.82 | 1.66 | 1.49 | 1.19 | 1.03 | 1.43 |
| Interest Cover(x) | 4.86 | 2.84 | 1.86 | 1.58 | 2.14 | 2.24 | 1.49 | 5.17 | 4 | 4.07 | 5.45 |
| Total Debt/Mcap(x) | 0.1 | 0.15 | 0.19 | 0.23 | 0.22 | 0.23 | 0.07 | 0.04 | 0.04 | 0.03 | 0.06 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 29.33 | 29.33 | 29.33 | 29.33 | 29.33 | 29.34 | 29.34 | 28.02 | 28.02 | 28.02 |
| FII | 46.25 | 45.63 | 43.92 | 45.37 | 45.27 | 42.74 | 43.49 | 44.2 | 43.54 | 42.62 |
| DII | 19.1 | 19.77 | 21.37 | 20.18 | 20.2 | 22.51 | 21.57 | 21.35 | 21.73 | 22.99 |
| Public | 5.32 | 5.26 | 5.38 | 5.12 | 5.19 | 5.41 | 5.61 | 6.43 | 6.71 | 6.37 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.22 | 4.22 | 4.22 | 4.22 | 4.22 | 4.22 | 4.22 | 4.03 | 4.03 | 4.03 |
| FII | 6.65 | 6.56 | 6.32 | 6.52 | 6.51 | 6.15 | 6.25 | 6.36 | 6.26 | 6.13 |
| DII | 2.75 | 2.84 | 3.07 | 2.9 | 2.9 | 3.24 | 3.1 | 3.07 | 3.13 | 3.31 |
| Public | 0.76 | 0.76 | 0.77 | 0.74 | 0.75 | 0.78 | 0.81 | 0.92 | 0.96 | 0.92 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +14% | +14% | +14% | +15% |
| Operating Profit CAGR | +29% | +12% | +15% | +15% |
| PAT CAGR | +61% | +11% | +28% | +17% |
| Share Price CAGR | +17% | +18% | +20% | +19% |
| ROE Average | +21% | +17% | +15% | +11% |
| ROCE Average | +21% | +19% | +19% | +14% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 29.33 | 29.33 | 29.33 | 29.33 | 29.33 | 29.34 | 29.34 | 28.02 | 28.02 | 28.02 |
| FII | 46.25 | 45.63 | 43.92 | 45.37 | 45.27 | 42.74 | 43.49 | 44.2 | 43.54 | 42.62 |
| DII | 19.1 | 19.77 | 21.37 | 20.18 | 20.2 | 22.51 | 21.57 | 21.35 | 21.73 | 22.99 |
| Public | 70.67 | 70.67 | 70.67 | 70.67 | 70.67 | 70.66 | 70.66 | 71.98 | 71.98 | 71.98 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.22 | 4.22 | 4.22 | 4.22 | 4.22 | 4.22 | 4.22 | 4.03 | 4.03 | 4.03 |
| FII | 6.65 | 6.56 | 6.32 | 6.52 | 6.51 | 6.15 | 6.25 | 6.36 | 6.26 | 6.13 |
| DII | 2.75 | 2.84 | 3.07 | 2.9 | 2.9 | 3.24 | 3.1 | 3.07 | 3.13 | 3.31 |
| Public | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.35 | 10.35 | 10.35 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 | 14.38 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.